Person:
Arévalo Pérez, Beatriz

Loading...
Profile Picture
First Name
Beatriz
Last Name
Arévalo Pérez
Affiliation
Universidad Complutense de Madrid
Faculty / Institute
Ciencias Químicas
Department
Química Analítica
Area
Identifiers
UCM identifierScopus Author IDDialnet ID

Search Results

Now showing 1 - 6 of 6
  • Item
    Paving the Way for Reliable Alzheimer’s Disease Blood Diagnosis by Quadruple Electrochemical Immunosensing
    (ChemElectroChem, 2022) Valverde de la Fuente, Alejandro; Gordón Pidal, José María; Montero Calle, Ana; Arévalo Pérez, Beatriz; Serafín González-Carrato, Verónica; Calero, Miguel; Moreno Guzmán, María; López, Miguel Ángel; Escarpa, Alberto; Yáñez Sedeño, Paloma; Barderas, Rodrigo; Campuzano Ruiz, Susana; Pingarrón Carrazón, José Manuel
    Alzheimer’s disease (AD), the most common neurodegenerative disorder, demands new cost-effective and easy-to-use strategies for its reliable detection, mainly in the preclinical stages. Here, we report the first immunoplatform for the electrochemical multidetermination of four candidate protein biomarkers in blood, neurofilament light chain (NfL), Tau, phosphorylated Tau (p-Tau) and TAR DNA-Binding Protein 43 (TDP-43). It involves implementation of sandwich-type immunoassays and enzymatic labelling with horseradish peroxidase (HRP) on the surface of magnetic microbeads (MBs). Amperometric detection is performed after depositing the magnetic immunoconjugates on disposable quadruple transduction platforms by monitoring the enzymatic reduction of H2O2 mediated by hydroquinone (HQ). The immunoplatform achieved LOD values smaller than the content of target biomarkers in plasma of healthy subjects, with RSD values.
  • Item
    Fast and sensitive diagnosis of autoimmune disorders through amperometric biosensing of serum anti-dsDNA autoantibodies
    (Biosensors & Bioelectronics, 2020) López Ruíz, Beatriz ; Arévalo Pérez, Beatriz; Serafín González-Carrato, Verónica; Sánchez-Paniagua López, Marta; Montero Calle, Ana; Barderas Manchado, Rodrigo; López Ruiz, María Beatriz; Campuzano Ruiz, Susana; Yáñez-Sedeño Orive, Paloma; Pingarrón Carrazón, José Manuel
    This work reports the first amperometric biosensor involving the use of neutravidin-functionalized magnetic microbeads (NA-MBs) modified with a biotinylated-anti-dsDNA (b-dsDNA) as efficient magnetic microcarriers to selectively capture anti-dsDNA autoantibodies (IgG, IgA and IgM AAbs) present in the sera of patients with rheumatoid arthritis (RA). Subsequently, the attached anti-dsDNA AAbs are detected with a mixture of conventional HRP-labeled secondary antibodies (HRP-anti-human IgG/IgM/IgA mixture). The biorecognition event is monitored by amperometric transduction using the hydroquinone (HQ)/H2O2 system upon capturing the modified MBs on the surface of screen-printed carbon electrodes (SPCEs). The developed bioplatform exhibits a linear calibration plot ranging from 1 to 200 IU mL−1 with a LOD of 0.3 IU mL−1 for anti-dsDNA AAbs standards. In addition, the biosensor allows performing the determination of the anti-dsDNA AAbs levels directly in 100-times diluted serum samples from patients diagnosed with RA and in just 75 min. The obtained results are in agreement with those provided by an ELISA kit and allow discrimination between positive and negative samples.
  • Item
    Anti-double stranded DNA antibodies: Electrochemical isotyping in autoimmune and neurological diseases
    (Analytica Chimica Acta, 2023) Arévalo Pérez, Beatriz; Serafín González-Carrato, Verónica; Garranzo-Asensio, María; Montero-Calle, Ana; Barderas, Rodrigo; Yáñez-Sedeño Orive, Paloma; Campuzano Ruiz, Susana; Pingarrón Carrazón, José Manuel
    This work reports the first amperometric biosensor for the simultaneous determination of the single or total content of the most relevant human immunoglobulin isotypes (hIgs) of anti-dsDNA antibodies, dsDNA-hIgG, dsDNA-hIgM, dsDNA-hIgA and dsDNA-three hIgs, which are considered relevant biomarkers in prevalent autoimmune diseases such as systemic lupus erythematosus (SLE) as well as of interest in neurodegenerative diseases such as Alzheimer’s disease (AD). The bioplatform involves the use of neutravidin-functionalized magnetic microparticles (NA-MBs) modified with a laboratory-prepared biotinylated human double-stranded DNA (b-dsDNA) for the efficient capture of specific autoantibodies that are enzymatically labeled with horseradish peroxidase (HRP) enzyme using specific secondary antibodies for each isotype or a mixture of secondary antibodies for the total content of the three isotypes. Transduction was performed by amperometry (− 0.20 V vs. the Ag pseudo-reference electrode) using the H2O2/hydroquinone (HQ) system after trapping the resulting magnetic bioconjugates on each of the four working electrodes of a disposable quadruple transduction platform (SP4CEs). The bioplatform demonstrated attractive operational characteristics for clinical application and was employed to determine the individual or total hIgs classes in serum from healthy individuals and from patients diagnosed with SLE and AD. The target concentrations in AD patients are provided for the first time in this work. In addition, the results for SLE patients and control individuals agree with those obtained by applying ELISA tests as well as with the clinical ranges reported by other authors, using individual detection methodologies restricted to centralized settings or clinical laboratories.
  • Item
    Binary MoS2 nanostructures as nanocarriers for amplification in multiplexed electrochemical immunosensing: simultaneous determination of B cell activation factor and proliferation-induced signal immunity-related cytokines
    (Microchimica Acta, 2022) Arévalo Pérez, Beatriz; Blázquez García, Marina; Valverde de la Fuente, Alejandro; Serafín González-Carrato, Verónica; Montero Calle, Ana; Solís Fernández, Guillermo; Barderas Manchado, Rodrigo; Campuzano Ruiz, Susana; Yáñez Sedeño, Paloma; Pingarron, José M.
    A dual immunosensor is reported for the simultaneous determination of two important immunity-related cytokines: BAFF (B cell activation factor) and APRIL (a proliferation-induced signal). Sandwich-type immunoassays with specifc antibodies (cAbs) and a strategy for signal amplifcation based on labelling the detection antibodies (dAbs) with binary MoS2/ MWCNTs nanostructures and using horseradish peroxidase (HRP) were implemented. Amperometric detection was carried out at screen-printed dual carbon electrodes (SPdCEs) through the hydroquinone HQ/H2O2 system. The developed dual immunosensor provided limit of detection (LOD) of 0.08 and 0.06 ng mL−1 for BAFF and APRIL, respectively, and proved to be useful for the determination of both cytokines in cancer cell lysates and serum samples from patients diagnosed with autoimmune diseases and cancer. The obtained results agreed with those found using ELISA methodologies.
  • Item
    Phage-Derived and Aberrant HaloTag Peptides Immobilized on Magnetic Microbeads for Amperometric Biosensing of Serum Autoantibodies and Alzheimer's Disease Diagnosis
    (Analysis & Sensing, 2021) Valverde de la Fuente, Alejandro; Montero Calle, Ana; Arévalo Pérez, Beatriz; San Segundo Acosta, Pablo; Serafín González-Carrato, Verónica; Alonso Navarro, Miren; Solís Fernández, Guillermo; Pingarrón Carrazón, José Manuel; Campuzano Ruiz, Susana; Barderas Manchado, Rodrigo
    An electrochemical biosensing platform for serum autoantibodies (AAbs) detection is reported in this work, exploiting for the first time six Alzheimer's disease (AD)-specific phage-derived and frameshift aberrant HaloTag peptides as receptors, immobilized on magnetic microbeads (MBs) surface and captured on disposable electrodes to perform amperometric detection. Operational analytical characteristics and clinical diagnostic ability of the bioplatform were probed in optimized key experimental conditions by analysing serum AAbs of AD patients and healthy subjects. The value of 100% obtained for AUC, sensitivity, and selectivity from the all peptides combined ROC curve, indicate full AD-diagnostic capability of the methodology, which was further implemented, as proof of concept, in a POC multiplexing platform to detect the signature in a single test over clinically actionable times (1 h 15 min), opening great promise for the type of diagnosis and AD patients’ monitoring follow-up currently pursued.
  • Item
    Enhanced determination of fertility hormones in saliva at disposable immunosensing platforms using a custom designed field-portable dual potentiostat
    (Sensors and Actuators B: Chemical, 2019) Serafín González-Carrato, Verónica; Arévalo Pérez, Beatriz; Martínez-García, Gonzalo; Aznar-Poveda, Juan; Lopez-Pastor, José Antonio; Beltrán-Sánchez, J. Francisco; Garcia-Sanchez Antonio, Javier; Garcia-Haro, Juan; Campuzano Ruiz, Susana; Yáñez-Sedeño Orive, Paloma; Pingarrón Carrazón, José Manuel
    This work describes a new electroanalytical device for the simultaneous and reliable determination of two fertility relevant hormones (luteinizing hormone, LH, and progesterone, P4) in saliva. The device is constructed using a custom designed and field-portable potentiostat where dual disposable immunosensing platform are connected. The immunosensors are based on sandwich-type and competitive immunoassays implemented onto magnetic microbeads (MBs) functionalized with Neutravidin and Protein G for the determination of LH and P4, respectively. Amperometric detection performed at −0.20 V vs the Ag pseudo-reference electrode using the H2O2/hydroquinone (HQ) system was employed as the transduction technique after placing the MBs with immunocomplexes for each target hormone on the appropriate working electrode of screen-printed dual carbon electrodes (SPdCEs). The method exhibits high sensitivity and selectivity for the target hormones providing detection limits of 1.7 pg mL−1 and 0.10 mIU mL−1 for P4 and LH, respectively, with a 1 h test time. The applicability of the method was confirmed by determining both hormones in saliva samples from different volunteers providing results comparable to those obtained using amperometric transduction with a commercial potentiostat and with ELISA methodologies involving the same immunoreagents for each target hormone.